Reassessing human adipose tissue

AM Cypess - New England Journal of Medicine, 2022 - Mass Medical Soc
Reassessing Human Adipose Tissue Adipose tissue can more than double in mass and
then return to baseline. This review discusses the functional roles of human white and brown …

Aspects of the tumor microenvironment involved in immune resistance and drug resistance

K Khalaf, D Hana, JTT Chou, C Singh… - Frontiers in …, 2021 - frontiersin.org
The tumor microenvironment (TME) is a complex and ever-changing “rogue organ”
composed of its own blood supply, lymphatic and nervous systems, stroma, immune cells …

ImmunoPET: concept, design, and applications

W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

[HTML][HTML] Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut

JP Lynch, C González-Prieto, AZ Reeves, S Bae… - Cell Host & Microbe, 2023 - cell.com
Drug platforms that enable the directed delivery of therapeutics to sites of diseases to
maximize efficacy and limit off-target effects are needed. Here, we report the development of …

Brown adipose tissue—a translational perspective

AC Carpentier, DP Blondin, F Haman… - Endocrine …, 2023 - academic.oup.com
Brown adipose tissue (BAT) displays the unique capacity to generate heat through
uncoupled oxidative phosphorylation that makes it a very attractive therapeutic target for …

Brown adipose tissue energy metabolism in humans

AC Carpentier, DP Blondin, KA Virtanen… - Frontiers in …, 2018 - frontiersin.org
The demonstration of metabolically active brown adipose tissue (BAT) in humans primarily
using positron emission tomography coupled to computed tomography (PET/CT) with the …

Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice

YJ **e, M Dougan, N Jailkhani, J Ingram… - Proceedings of the …, 2019 - pnas.org
Chimeric antigen receptor (CAR) T cell therapy has been successful in clinical trials against
hematological cancers, but has experienced challenges in the treatment of solid tumors …

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

I Zerdes, A Matikas, J Bergh, GZ Rassidakis… - Oncogene, 2018 - nature.com
The programmed death protein 1 (PD-1) and its ligand (PD-L1) represent a well-
characterized immune checkpoint in cancer, effectively targeted by monoclonal antibodies …

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy

A Quijano-Rubio, AM Bhuiyan, H Yang, I Leung… - Nature …, 2023 - nature.com
The therapeutic potential of recombinant cytokines has been limited by the severe side
effects of systemic administration. We describe a strategy to reduce the dose-limiting …

Exploiting nanobodies' singular traits

JR Ingram, FI Schmidt, HL Ploegh - Annual review of …, 2018 - annualreviews.org
The unique class of heavy chain–only antibodies, present in Camelidae, can be shrunk to
just the variable region of the heavy chain to yield VHHs, also called nanobodies. About one …